Oncolytics Biotech (NASDAQ:ONCY – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 11th. Analysts expect Oncolytics Biotech to post earnings of ($0.09) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Oncolytics Biotech (NASDAQ:ONCY – Get Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Oncolytics Biotech Price Performance
Shares of NASDAQ ONCY opened at $1.21 on Thursday. The company has a market capitalization of $70.02 million, a price-to-earnings ratio of -3.18 and a beta of 2.26. The business has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.38. Oncolytics Biotech has a 1 year low of $0.80 and a 1 year high of $2.38.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- Get a free copy of the StockNews.com research report on Oncolytics Biotech (ONCY)
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Is Nike An Undervalued Opportunity for Investors?
- Proposed Tesla Stock Split Drives EV Market Higher
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.